Kimelman & Baird LLC reduced its position in shares of STERIS plc (NYSE:STE - Free Report) by 10.5% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 25,673 shares of the medical equipment provider's stock after selling 3,026 shares during the quarter. Kimelman & Baird LLC's holdings in STERIS were worth $5,277,000 as of its most recent SEC filing.
A number of other large investors have also made changes to their positions in the company. Avalon Trust Co bought a new position in shares of STERIS during the 4th quarter valued at approximately $30,000. Human Investing LLC bought a new position in shares of STERIS during the 4th quarter valued at approximately $31,000. Anfield Capital Management LLC grew its stake in shares of STERIS by 100.0% during the 4th quarter. Anfield Capital Management LLC now owns 182 shares of the medical equipment provider's stock valued at $37,000 after acquiring an additional 91 shares during the period. Central Pacific Bank Trust Division grew its stake in shares of STERIS by 65.5% during the 4th quarter. Central Pacific Bank Trust Division now owns 192 shares of the medical equipment provider's stock valued at $39,000 after acquiring an additional 76 shares during the period. Finally, Manchester Capital Management LLC grew its stake in shares of STERIS by 182.7% during the 4th quarter. Manchester Capital Management LLC now owns 212 shares of the medical equipment provider's stock valued at $44,000 after acquiring an additional 137 shares during the period. 94.69% of the stock is currently owned by institutional investors.
Analysts Set New Price Targets
A number of research firms recently commented on STE. Piper Sandler boosted their price target on STERIS from $260.00 to $265.00 and gave the stock an "overweight" rating in a report on Monday, February 3rd. Stephens reaffirmed an "overweight" rating and issued a $240.00 price objective on shares of STERIS in a research report on Thursday, February 6th. Finally, JMP Securities reissued a "market outperform" rating and set a $265.00 price target on shares of STERIS in a research report on Thursday, February 6th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $258.75.
View Our Latest Stock Analysis on STE
STERIS Stock Up 0.2 %
Shares of NYSE STE traded up $0.48 during mid-day trading on Tuesday, reaching $228.29. 454,011 shares of the company were exchanged, compared to its average volume of 500,986. The company has a quick ratio of 1.40, a current ratio of 2.13 and a debt-to-equity ratio of 0.32. The stock has a market cap of $22.43 billion, a price-to-earnings ratio of 48.47 and a beta of 0.92. STERIS plc has a 1 year low of $197.82 and a 1 year high of $248.24. The firm has a 50-day moving average of $219.65 and a 200 day moving average of $222.31.
STERIS (NYSE:STE - Get Free Report) last issued its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $2.32 earnings per share for the quarter, missing analysts' consensus estimates of $2.33 by ($0.01). STERIS had a return on equity of 13.91% and a net margin of 8.66%. On average, research analysts expect that STERIS plc will post 9.08 earnings per share for the current year.
STERIS Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 21st. Stockholders of record on Thursday, February 20th will be paid a $0.57 dividend. This represents a $2.28 annualized dividend and a dividend yield of 1.00%. The ex-dividend date is Thursday, February 20th. STERIS's payout ratio is 48.41%.
STERIS Profile
(
Free Report)
STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.
See Also

Before you consider STERIS, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and STERIS wasn't on the list.
While STERIS currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.